TAT and Cognitive impairment: The feasibility of Tat‐C16 peptide as a therapeutic drug hinges on several factors, including its ability to cross the blood–brain barrier (BBB), its stability and bioavailability in the central nervous system (CNS), and its specificity in targeting the pathways involved in hypoxia‐induced cognitive impairment.42, 43, 44